FOXO4-DRI · Research brief

What Is FOXO4-D-Retro-Inverso Same as FOXO4-DRI? | Real

Real Peptides Research TeamEditorial

Updated April 7, 20268 min read

44 WORDS

Short answer

What Is FOXO4-D-Retro-Inverso Same as FOXO4-DRI? Research from Erasmus University Medical Center's 2017 Nature paper established FOXO4-DRI as a senolytic peptide capable of selectively inducing apoptosis in senescent cells while sparing healthy cells. A mechanism that addresses one of aging's most fundamental biological drivers.

Key takeaways

FOXO4-D-Retro-Inverso and FOXO4-DRI are identical peptides. The DRI abbreviation condenses the full structural descriptor D-Retro-Inverso into laboratory shorthand.
The peptide consists of 15 D-amino acids in reversed sequence with inverted peptide bonds, a retro-inverso design that maintains p53 binding affinity while conferring protease resistance and extending half-life beyond 72 hours in biological systems.
FOXO4-DRI disrupts the p53-FOXO4 protein complex in senescent cells, releasing p53 to activate BAX/BAK-mediated apoptosis pathways selectively in cells that rely on FOXO4-p53 binding to evade programmed death.
The 2017 Nature study demonstrated 30–40% senescent cell apoptosis within 48 hours at 5–10 µM FOXO4-DRI, with less than 5% apoptosis in non-senescent control cells at equivalent concentrations. A therapeutic window driven by differential FOXO4 expression.
Research catalogs and peptide suppliers now list FOXO4-DRI as the standard name, with FOXO4-D-Retro-Inverso appearing as a structural clarifier in technical specifications to eliminate ambiguity across publications.

What Is FOXO4-D-Retro-Inverso Same as FOXO4-DRI?

Research from Erasmus University Medical Center's 2017 Nature paper established FOXO4-DRI as a senolytic peptide capable of selectively inducing apoptosis in senescent cells while sparing healthy cells. A mechanism that addresses one of aging's most fundamental biological drivers. The peptide's full designation, FOXO4-D-Retro-Inverso, describes the structural modifications that make it work: D-amino acid substitution and retro-inverso configuration create a protease-resistant molecule that maintains binding affinity for p53 while gaining exceptional stability in biological systems.

Our team has worked extensively with researchers investigating senolytic compounds. The naming convention creates confusion unnecessarily. Both FOXO4-D-Retro-Inverso and FOXO4-DRI refer to the same 15-residue peptide sequence. The 'DRI' abbreviation simply condenses the structural descriptor into shorthand.

What is FOXO4-D-Retro-Inverso same as FOXO4-DRI?

FOXO4-D-Retro-Inverso and FOXO4-DRI are identical peptides consisting of 15 D-amino acids in retro-inverso configuration, engineered to disrupt the p53-FOXO4 protein complex that keeps senescent cells in arrested state. The molecule prevents FOXO4 from binding to p53, allowing p53 to trigger apoptosis selectively in senescent cells. Those cells that have stopped dividing but resist programmed death. Research published in Nature demonstrated that FOXO4-DRI administration restored fitness markers and reduced senescence burden in naturally aged mice within weeks.

The confusion around whether FOXO4-D-Retro-Inverso is the same as FOXO4-DRI stems from incomplete naming conventions in early literature. Research groups initially published under both names before standardizing on FOXO4-DRI as the primary designation. The 'D-Retro-Inverso' portion describes the chemical architecture: D-amino acids (mirror-image forms of natural L-amino acids) arranged in reverse sequence with inverted peptide bond orientation. This isn't a different compound. It's the full technical name for what's commonly abbreviated as FOXO4-DRI. This article covers the structural basis for why FOXO4-D-Retro-Inverso and FOXO4-DRI are identical, the mechanism by which the peptide functions as a senolytic agent, and what implications this has for research into cellular aging.

The Structural Identity Between FOXO4-D-Retro-Inverso and FOXO4-DRI

FOXO4-D-Retro-Inverso same as FOXO4-DRI because both names describe the exact 15-amino-acid sequence with identical structural modifications. The original wild-type FOXO4 peptide consists of L-amino acids in standard orientation. The naturally occurring form that binds p53 but degrades rapidly under enzymatic attack. Researchers at Erasmus modified this baseline sequence by substituting all L-amino acids with D-amino acids (the mirror-image stereoisomers) and reversing the sequence direction while inverting peptide bond polarity. This retro-inverso design preserves the spatial arrangement of side chains. Maintaining binding affinity to the target protein. While rendering the backbone unrecognizable to proteases.

D-amino acids confer protease resistance because mammalian peptidases evolved to cleave L-amino acid bonds specifically. Inverting the backbone orientation (retro-inverso) repositions functional groups to maintain binding interactions despite the backbone reversal. The result is a peptide with 100+ hour half-life in serum compared to under 30 minutes for the L-amino acid parent sequence. Published pharmacokinetic data from the original Nature paper showed FOXO4-DRI maintained detectable plasma concentrations 72 hours post-administration in mouse models. A stability profile that makes repeated dosing feasible.

The DRI abbreviation emerged as laboratory shorthand during initial characterization. Early publications used 'FOXO4-D-Retro-Inverso' in full text and methods sections, then introduced 'FOXO4-DRI' as the abbreviated form in figures and discussion. By 2018, most research groups had adopted FOXO4-DRI as the standard nomenclature. Peptide suppliers and research databases now list both names interchangeably. Real Peptides catalogues this compound under FOXO4-DRI with the full structural name provided in technical specifications to eliminate ambiguity.

How FOXO4-D-Retro-Inverso (FOXO4-DRI) Disrupts Senescent Cell Survival

Senescent cells accumulate with age and in response to DNA damage, oxidative stress, or oncogenic signaling. Unlike cells undergoing normal apoptosis, senescent cells enter permanent growth arrest while remaining metabolically active. Secreting pro-inflammatory cytokines, matrix metalloproteinases, and growth factors collectively termed the senescence-associated secretory phenotype (SASP). This phenotype drives tissue dysfunction, chronic inflammation, and age-related pathology. The p53-FOXO4 interaction is central to senescent cell survival: p53 normally triggers apoptosis in damaged cells, but FOXO4 binding sequesters p53 in the nucleus, preventing it from activating pro-apoptotic genes.

FOXO4-DRI competitively inhibits this interaction. The peptide's binding domain mimics the segment of FOXO4 that contacts p53, occupying the binding site and preventing endogenous FOXO4 from tethering p53. With p53 released, it translocates to mitochondria and activates BAX/BAK-mediated apoptosis pathways. Critically, this mechanism is selective: healthy proliferating cells express lower FOXO4 levels and don't rely on p53 sequestration for survival. Senescent cells, which maintain elevated FOXO4 to enforce growth arrest, lose viability when that block is removed. The 2017 Nature study quantified this selectivity. FOXO4-DRI induced apoptosis in 30–40% of senescent fibroblasts within 48 hours while producing less than 5% apoptosis in non-senescent controls at equivalent concentrations.

Our experience working with research teams using FOXO4-DRI confirms what the literature shows: the peptide's efficacy depends entirely on target cell senescence status. Standard toxicity assays in proliferating cell lines show minimal effect at doses that clear senescent populations in co-culture models. The therapeutic window exists because the mechanism exploits a vulnerability unique to senescent cells. Their dependence on FOXO4-p53 binding to avoid death despite accumulated damage.

FOXO4-D-Retro-Inverso Same as FOXO4-DRI: Comparison Across Research Applications

Application Context	FOXO4-D-Retro-Inverso Designation	FOXO4-DRI Designation	Structural Specifications	Reported Outcomes	Professional Assessment
In vitro senolytic screening	Used in early Erasmus publications (2016–2017)	Standard nomenclature in follow-up studies (2018+)	15-mer D-amino acid retro-inverso peptide, MW ~1850 Da	Selective apoptosis induction in senescent IMR-90 fibroblasts at 5–10 µM	Identical molecule. Naming convention shifted as field standardized terminology
Mouse aging models	Full name appears in methods sections	Abbreviated form used in figures and discussion	Administered subcutaneously at 5 mg/kg 3× weekly	Improved physical fitness markers, reduced p16^INK4a^ expression in kidney and liver	Both names describe same intervention. Results cross-reference directly
Peptide synthesis and supply	Occasionally listed by full structural descriptor	Predominant catalog name in commercial and research inventories	Synthesized via solid-phase peptide synthesis (SPPS) with D-amino acid incorporation	Purity ≥95% by HPLC, identity confirmed by mass spectrometry	FOXO4-DRI is the accepted shorthand. Structural name clarifies modification type
Pharmacokinetic studies	Rare in recent literature	Standard designation in PK/PD characterization	Half-life >72 hours in mouse serum, protease-resistant backbone	Detectable plasma levels 3 days post-injection	Extended half-life validates retro-inverso design. Both names denote same PK profile

What If: FOXO4-D-Retro-Inverso and FOXO4-DRI Scenarios

What If a Research Protocol Lists Only FOXO4-D-Retro-Inverso?

Order FOXO4-DRI from your peptide supplier. They are the same molecule. The full structural name FOXO4-D-Retro-Inverso appears in older literature and detailed methods sections, but commercial suppliers catalog it under the abbreviated form FOXO4-DRI. Verify the sequence matches the 15-amino-acid D-retro-inverso configuration in the original Nature paper if you're replicating published work.

What If FOXO4-DRI Shows No Senolytic Effect in My Cell Line?

Confirm that your target cells are genuinely senescent. Not quiescent or contact-inhibited. Senescence markers include elevated p16^INK4a^, SA-β-galactosidase activity, and SASP cytokine secretion. FOXO4-DRI's mechanism requires FOXO4 overexpression and p53-FOXO4 binding, which don't occur in all arrested cell states. If markers confirm senescence but apoptosis doesn't occur, check peptide purity and storage. Degraded or improperly stored FOXO4-DRI loses binding affinity.

What If I Need to Compare FOXO4-DRI to Other Senolytic Agents?

FOXO4-DRI's selectivity profile differs from BCL-2 family inhibitors like navitoclax or dasatinib+quercetin combinations. FOXO4-DRI targets p53-dependent senescent cells specifically, while BCL-2 inhibitors act on cells with elevated anti-apoptotic protein expression regardless of senescence status. In comparative studies, FOXO4-DRI produced fewer off-target effects in proliferating tissues. The peptide's mechanism exploits senescence-specific dependencies rather than general apoptosis pathways.

The Unambiguous Truth About FOXO4-D-Retro-Inverso and FOXO4-DRI

Here's the honest answer: if you see FOXO4-D-Retro-Inverso in a protocol or publication, it means FOXO4-DRI. Not a variant. Not an isomer. The exact same peptide. The structural descriptor 'D-Retro-Inverso' was included in early papers to clarify the modification strategy. D-amino acids in reversed sequence with inverted bonds. But the research community standardized on the abbreviated form FOXO4-DRI within two years of the original Nature publication. Any supplier listing them separately is either repackaging the same compound under multiple names or hasn't updated their catalog nomenclature.

The continued use of both names creates unnecessary confusion in procurement and experimental design. We've seen research teams delay experiments because they couldn't confirm whether FOXO4-D-Retro-Inverso matched the FOXO4-DRI used in reference studies. The peptide sequence is publicly available in the original Erasmus paper's supplementary data. Compare any supplier's specifications against that sequence and you'll confirm identity. The mechanism, pharmacokinetics, and senolytic efficacy are identical because the molecule is identical. The distinction exists only in naming convention, not in chemistry or function.

The Broader Context of Senolytic Peptide Research and FOXO4-DRI

FOXO4-D-Retro-Inverso same as FOXO4-DRI represents one approach within the larger senolytic research field. Compounds designed to selectively eliminate senescent cells. The peptide's value lies in its mechanistic specificity: rather than broadly inhibiting survival pathways (as small-molecule senolytics like navitoclax do), FOXO4-DRI targets a protein-protein interaction unique to senescent cell biology. This precision reduces off-target toxicity but also narrows the range of senescent cell types affected. Cells with low FOXO4 expression or p53-independent survival mechanisms may resist FOXO4-DRI-induced apoptosis.

Follow-up studies since 2017 have explored combination strategies. Pairing FOXO4-DRI with BCL-2 inhibitors targets both p53-dependent and BCL-2-dependent senescent populations, achieving broader clearance than either agent alone. Research groups have also investigated tissue-specific delivery. Conjugating FOXO4-DRI to homing peptides or encapsulating it in targeted nanoparticles to concentrate the peptide in organs with high senescence burden like aged kidney or liver. These approaches aim to maximize therapeutic benefit while minimizing systemic exposure.

Our work supplying research-grade peptides has given us perspective on the practical constraints researchers face. FOXO4-DRI synthesis requires precise D-amino acid incorporation at every position. A deviation in even one residue compromises protease resistance and binding affinity. Real Peptides produces FOXO4-DRI through small-batch solid-phase peptide synthesis (SPPS) with post-synthesis HPLC purification to ≥95% purity and mass spectrometry confirmation of the exact molecular weight. The peptide's stability advantage over L-amino acid analogs means it can be stored lyophilized at −20°C for extended periods without degradation. A logistical benefit for labs running long-term aging studies.

The naming inconsistency between FOXO4-D-Retro-Inverso and FOXO4-DRI will likely fade as newer publications reference only the abbreviated form. Researchers entering the senolytic field should recognize both names as interchangeable to avoid procurement errors or misinterpretation of published data. The peptide's mechanism. Competitive inhibition of p53-FOXO4 binding leading to selective senescent cell apoptosis. Remains the critical detail, not the specific label used to order it.

FOXO4-D-Retro-Inverso same as FOXO4-DRI isn't a trivial naming clarification. It's a functional recognition that one peptide sequence, engineered with specific structural modifications, has been described under multiple names across the research literature. Understanding this equivalence allows researchers to cross-reference studies, replicate protocols, and make informed decisions about peptide sourcing without second-guessing whether they're working with the correct compound. The molecule's identity is fixed; the nomenclature flexibility is a remnant of early-stage research communication that standardized as the field matured.

Questions

Yes, FOXO4-D-Retro-Inverso and FOXO4-DRI are identical peptides with the same 15-amino-acid sequence, D-amino acid substitution, and retro-inverso backbone configuration. The ‘DRI’ abbreviation condenses the full structural descriptor into laboratory shorthand — both names reference the same molecule published in the 2017 Nature study by Baar et al. Peptide suppliers list both names interchangeably, with FOXO4-DRI now serving as the standard catalog designation.

FOXO4-DRI competitively inhibits the p53-FOXO4 protein interaction that keeps senescent cells alive despite DNA damage. Senescent cells express elevated FOXO4 levels to sequester p53 in the nucleus and prevent apoptosis; FOXO4-DRI displaces endogenous FOXO4, releasing p53 to activate BAX/BAK-mediated cell death pathways. Healthy proliferating cells express lower FOXO4 and don’t rely on this survival mechanism — published data from the original Nature paper showed less than 5% apoptosis in non-senescent cells at concentrations that induced 30–40% apoptosis in senescent populations within 48 hours.

FOXO4-DRI exhibits a half-life exceeding 72 hours in mouse serum due to its D-amino acid composition and retro-inverso backbone configuration, which render it resistant to protease degradation. This extended half-life represents a 100+ fold improvement over the L-amino acid parent sequence, which degrades in under 30 minutes. Pharmacokinetic studies published alongside the original Nature paper demonstrated detectable plasma concentrations 72 hours post-subcutaneous injection at 5 mg/kg, enabling practical dosing schedules for in vivo aging research.

No, FOXO4-DRI specifically targets senescent cells that rely on p53-FOXO4 binding for survival — primarily those with functional p53 and elevated FOXO4 expression. Senescent cells with p53 mutations, low FOXO4 levels, or alternative survival pathways (such as BCL-2 family protein upregulation) may resist FOXO4-DRI-induced apoptosis. Combination approaches pairing FOXO4-DRI with BCL-2 inhibitors or other senolytic agents achieve broader senescent cell clearance by targeting multiple survival dependencies simultaneously.

Published in vitro studies demonstrate senolytic activity at FOXO4-DRI concentrations between 5–10 µM in cultured senescent fibroblasts, with maximal apoptosis induction occurring within 48 hours of exposure. Lower concentrations (1–3 µM) produce modest effects, while concentrations above 20 µM do not significantly increase efficacy beyond the 10 µM benchmark. These concentrations correspond to the peptide’s binding affinity for the p53-FOXO4 interaction site — effective displacement requires sufficient peptide concentration to outcompete endogenous FOXO4.

Store lyophilized FOXO4-DRI at −20°C in a desiccated environment to prevent moisture-induced degradation. Once reconstituted in sterile buffer (typically PBS or bacteriostatic water), the peptide should be aliquoted and stored at −80°C for long-term use or at 4°C for short-term use within 7 days. The D-amino acid backbone confers exceptional stability compared to L-amino acid peptides, but repeated freeze-thaw cycles should be avoided — aliquoting prevents degradation from temperature fluctuations.

The abbreviated form FOXO4-DRI emerged as laboratory shorthand during the peptide’s initial characterization and was adopted as standard nomenclature by 2018 for brevity in figures, discussions, and catalog listings. Early publications used the full structural name ‘FOXO4-D-Retro-Inverso’ in methods sections to clarify the modification strategy — D-amino acids in reversed sequence with inverted peptide bonds — but the research community standardized on the concise abbreviation as the peptide gained recognition in senolytic literature.

FOXO4-DRI operates through a distinct mechanism compared to small-molecule senolytics like dasatinib or quercetin, which inhibit BCL-2 family proteins or tyrosine kinases broadly expressed in senescent and non-senescent cells. FOXO4-DRI specifically disrupts the p53-FOXO4 protein interaction — a dependency unique to certain senescent cell types — producing greater selectivity but narrower coverage. Dasatinib and quercetin combinations clear a wider range of senescent populations by targeting general anti-apoptotic pathways, but with higher potential for off-target effects in proliferating tissues.

Yes, FOXO4-DRI has been successfully administered in vivo in mouse aging models via subcutaneous injection at doses of 5 mg/kg three times weekly. The original 2017 Nature study demonstrated that this dosing regimen reduced senescence markers (p16^INK4a^ expression) in kidney and liver tissue, improved physical fitness parameters, and restored fur density in naturally aged mice. The peptide’s extended half-life (>72 hours) and protease resistance make it suitable for repeated dosing schedules required in chronic aging studies.

Researchers can obtain research-grade FOXO4-DRI from specialized peptide suppliers that perform small-batch solid-phase peptide synthesis (SPPS) with D-amino acid incorporation and post-synthesis HPLC purification to ≥95% purity. [Real Peptides](https://www.realpeptides.co/) provides FOXO4-DRI with mass spectrometry-confirmed identity and sequence fidelity, ensuring the exact molecular weight and D-retro-inverso configuration required for senolytic activity. Verify that any supplier lists both FOXO4-DRI and FOXO4-D-Retro-Inverso as interchangeable designations to avoid procurement confusion.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA